Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.83 |
| ▸ | DRD4 | P21917 | 6/20 | 0.77 |
| ▸ | DRD2 | P14416 | 6/20 | 0.77 |
| ▸ | DRD3 | P35462 | 6/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.77 |
| ▸ | HRH1 | P35367 | 4/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.77 |
| ▸ | HTR2A | P28223 | 4/20 | 0.77 |
| ▸ | HRH2 | P25021 | 3/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.77 |
| ▸ | HTR1A | P08908 | 3/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.77 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.77 |
| ▸ | DRD1 | P21728 | 3/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.77 |
| ▸ | HTR2C | P28335 | 3/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834014 | 0.91 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL19386241 | 0.87 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL29374082 | 0.87 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL94146 | 0.87 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL30324780 | 0.87 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL29482385 | 0.87 | HRH4 (1.00) | HRH4DRD4DRD2DRD3CHRM1 | |
| SCHEMBL7256287 | 0.86 | HRH4 (0.76) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL30903930 | 0.86 | HRH4 (0.98) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL4164270 | 0.86 | HRH4 (0.98) | HRH4DRD4DRD2DRD3CHRM1 | |
| Loxapine SCHEMBL41625 | 0.86 | HRH4 (0.98) | HRH4DRD4DRD2DRD3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200200765-A1 | BROAD SPECTRUM GPCR BINDING AGENTS | PROMEGA CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110136790-A1 | Tricyclic Heterocyclic Derivatives and Methods of Use | DE LERA RUIZ MANUEL | 2011-06-09 | — | — | US | disclosed |
| US-20110136790-A1 | Tricyclic Heterocyclic Derivatives and Methods of Use | DE LERA RUIZ MANUEL | 2011-06-09 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200200765-A1 | BROAD SPECTRUM GPCR BINDING AGENTS | GPR139, GPR4, GPR3 | HRH4 283/4885DRD4 618/4885DRD2 258/4885 |
| US-20110136790-A1 | Tricyclic Heterocyclic Derivatives and Methods of Use | GPR119, CNR1, CNR2 | HRH4 5/4885DRD4 1241/4885DRD2 594/4885 |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | HRH4 736/4885DRD4 1775/4885DRD2 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.